110 related articles for article (PubMed ID: 2068521)
21. Depression to ecstasy. The Neuropharmacology of Serotonin sponsored by the New York Academy of Sciences, New York, NY, USA, July 10-13, 1989.
Whitaker-Azmitia PM
New Biol; 1989 Nov; 1(2):145-8. PubMed ID: 2577368
[No Abstract] [Full Text] [Related]
22. The anatomy and biochemistry of headache.
Buzzi MG; Bonamini M; Cerbo R
Funct Neurol; 1993; 8(6):395-402. PubMed ID: 8150317
[No Abstract] [Full Text] [Related]
23. A review of the treatment of migraine.
Nightingale S
J Clin Hosp Pharm; 1984 Dec; 9(4):271-82. PubMed ID: 6396320
[No Abstract] [Full Text] [Related]
24. Agonists and antagonists of vascular receptors.
Saxena PR
Adv Neurol; 1982; 33():309-14. PubMed ID: 7034489
[No Abstract] [Full Text] [Related]
25. New migraine and pain research.
Hargreaves R
Headache; 2007 Apr; 47 Suppl 1():S26-43. PubMed ID: 17425708
[TBL] [Abstract][Full Text] [Related]
26. Drugs for migraine.
Treat Guidel Med Lett; 2004 Sep; 2(25):63-6. PubMed ID: 15529091
[No Abstract] [Full Text] [Related]
27. Present and future of 5-HT receptor agonists as antimigraine drugs.
Pauwels PJ; John GW
Clin Neuropharmacol; 1999; 22(3):123-36. PubMed ID: 10367177
[TBL] [Abstract][Full Text] [Related]
28. [Serotonin and migraine].
Hirose G
Nihon Naika Gakkai Zasshi; 2001 Apr; 90(4):595-600. PubMed ID: 11391905
[No Abstract] [Full Text] [Related]
29. 5-Hydroxytryptamine receptor subtypes and the pharmacology of migraine.
Peroutka SJ
Neurology; 1993 Jun; 43(6 Suppl 3):S34-8. PubMed ID: 8389009
[TBL] [Abstract][Full Text] [Related]
30. New vistas on 5-HT receptors and migraine.
Peroutka SJ
Prog Neuropsychopharmacol Biol Psychiatry; 1991; 15(2):191-7. PubMed ID: 1871321
[TBL] [Abstract][Full Text] [Related]
31. Unraveling the migraine mystery.
Gallagher RM
J Am Osteopath Assoc; 1990 Oct; 90(10):866. PubMed ID: 2094250
[No Abstract] [Full Text] [Related]
32. Biochemical pharmacological profile of migraine prophylactics of pizotifen type.
Dlohozková N; Metys J; Valchár M; Soucek R
Act Nerv Super (Praha); 1989 Dec; 31(4):300-1. PubMed ID: 2638122
[No Abstract] [Full Text] [Related]
33. Headache: classification, mechanism and principles of therapy, with particular reference to migraine.
Lance JW
Recenti Prog Med; 1989 Dec; 80(12):673-80. PubMed ID: 2516913
[TBL] [Abstract][Full Text] [Related]
34. Clinical characteristics of migraine patients.
Rasmussen BK
Cephalalgia; 1996 Feb; 16(1):4. PubMed ID: 8825692
[No Abstract] [Full Text] [Related]
35. The evolution of thinking about the role and site of action of serotonin in migraine.
Fanchamps A
Adv Neurol; 1982; 33():31-3. PubMed ID: 7055011
[No Abstract] [Full Text] [Related]
36. [In the pipeline. Triptans--new developments].
Link A; Link B
Pharm Unserer Zeit; 2002; 31(5):486-93. PubMed ID: 12369167
[No Abstract] [Full Text] [Related]
37. [Migraine: physiopathology, genetics and treatment aspects. The knowledge situation summarized].
Ormstad H; Amthor KF
Lakartidningen; 2008 Jul 23-Aug 5; 105(30-31):2098-102. PubMed ID: 18751448
[No Abstract] [Full Text] [Related]
38. Painful venous overdistension in migraine and serotonergic parameters.
Saxena P
Cephalalgia; 1996 Feb; 16(1):3. PubMed ID: 8825690
[No Abstract] [Full Text] [Related]
39. Selective, orally active 5-HT1D receptor agonists as potential antimigraine agents.
MacLeod AM; Street LJ; Reeve AJ; Jelley RA; Sternfeld F; Beer MS; Stanton JA; Watt AP; Rathbone D; Matassa VG
J Med Chem; 1997 Oct; 40(22):3501-3. PubMed ID: 9357515
[No Abstract] [Full Text] [Related]
40. Sumatriptan--a new treatment of migraine.
Neighbor ML
West J Med; 1993 Nov; 159(5):597-8. PubMed ID: 8279161
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
